Literature DB >> 3688740

[Combined ORL and neurosurgical approach in adenocarcinoma of the ethmoid. Preliminary results apropos of 15 cases].

D Brasnu1, F X Roux, A Fabre, M Menard, L Manolopoulos, J P Chodkiewicz, H Laccourreye.   

Abstract

Fifteen cases of adenocarcinoma of the ethmoid sinus treated by a combined subfrontal and transfacial approach after induction chemotherapy are reported. The surgical technique is described precisely including a paralateronasal approach combined with a bifrontocoronal incision, a bilateral ethmoidectomy and reconstruction of the anterior base of the skull by one sheets taken-out from the inner surface of the frontal flap or more recently madreporic coralline grafts; the dura is hermetically sealed and it is lined with a large galea flap. Results were as following: one post-operative death, no clinical rhinorrhea, no recurrence from the anterior cerebral fossa, one orbital and one sphenoidal recurrences. Surgical indications are discussed according to the different extensions of the tumor and a frontal lobe extension is not a contraindication. This surgical procedure should be employed for the adenocarcinomas of the ethmoid invading the superior cells even in the absence of lysis of the cribriform plate in order to avoid the endocranial recurrences.

Entities:  

Mesh:

Year:  1987        PMID: 3688740

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  2 in total

1.  The transfacial approach with naso-maxillary flap for tumors of the ethmoid and sphenoid.

Authors:  B Fougeront; P Cornu; F Chabolle; A Zouaoui; J Philippon; G Hidden; J Soudant
Journal:  Surg Radiol Anat       Date:  1990       Impact factor: 1.246

2.  Adenocarcinoma of the ethmoid sinuses. Results of a new protocol based on inductive chemotherapy combined with surgery. Four years experience.

Authors:  F X Roux; D Brasnu; M Menard; V Bassot; S Nguyen; S Donadieu; J L Chodkiewicz; H Laccourreye
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.